aventis

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Aventis Pharmaceuticals Lowers Injury Rates and Costs With Humantech

Aventis Pharmaceuticals, formerly Rhone-Poulenc Rorer, is a world leader in life sciences dedicated to treating and preventing human disease through the discovery, development, manufacture, and sale of innovative pharmaceutical products aimed at satisfying unmet medical needs. In 1989, the Kankakee, Illinois manufacturing plant of Aventis Pharmaceuticals employed 1,500 workers who...

Tags: Aventis, pharmaceutical company, worker, life science, accident, compensation, manufacturing, job

Case studies 2002-12-01

Additional Resources

Sanofi-Aventis bids 1.65 billion euros for control of Zentiva

PRAGUE AFP — French pharmaceutical group Sanofi-Aventis launched a bid worth 1.655 billion euros (2.6 billion dollars) for the 74.12 percent of Czech company Zentiva it does not already own on Friday. But the Zentiva board immediately urged shareholders to wait before taking any action. The...

Articles 2008-07-11

Bevil Joins Varsity Sports Media as Vice President of Sales

KNOXVILLE, Tenn. -- Chris Bevil has been named vice president of sales for Varsity Sports Media VSM. Bevil will be based in Knoxville, where he will be responsible for all sales management duties for VSM, and will work closely with Craig Baroncelli, VSM general manager and publisher, on marketing strategies...

Articles 2008-06-30

A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies

Report in Good Clinical Practice Journal GCPj Finds That Novartis Leads the Pack for Ongoing Trials in Autoimmune, Cardiovascular, and Metabolic Diseases Sanofi-aventis Takes the Top Rank for Ongoing Oncology Trials NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in...

Articles 2008-06-30

Federal Advisory Committee Votes to Include Newly Licensed Pentacel® Vaccine in Vaccines for Children Program

- New combination vaccine offers good fit to childhood immunization schedule providing protection with fewer shots - SWIFTWATER, Pa., June 26 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that its PentacelR, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and...

Articles 2008-06-26

A Competitor Analysis of the Antihypertensives Market Including Detailed Market Information and Major Companies Active in the Industry

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/1d8ee0/competitor_analysi) has announced the addition of the "Competitor Analysis: Antihypertensives" report to their offering. The Competitive Intelligence Report Antihypertensives as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of pulmonary artery hypertension, arterial hypertension, portal hypertension...

Articles 2008-06-25

Unity Square in New Brunswick Receives Historic Contribution Through NJ Neighborhood Revitalization Tax Credit Program

NEW BRUNSWICK, N.J., June 24 /PRNewswire/ -- NJ Department of Community Affairs is pleased to announce that sanofi-aventis allocates $1,000,000 to the Neighborhood Revitalization Tax Credit Program, NJ Department of Community Affairs. This is the largest contribution committed to one nonprofit organization since the inception of the New Jersey...

Articles 2008-06-24

U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel®

- PentacelR vaccine is the first 5-in-1 pediatric combination for immunization against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b Hib - SWIFTWATER, Pa. and LYON, France, June 23 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food...

Articles 2008-06-23

Sanofi strikes back in takeover battle for big Czech drug company

PRAGUE AFP — Czech-based generic drugs giant Zentiva was at the heart of a takeover tussle Wednesday after French group Sanofi-Aventis struck back with an offer countering a bid by local financial concern PPF. PPF, holding a 19.2 percent stake in Zentiva, which has substantial markets in Slovakia,...

Articles 2008-06-18

Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services

NEW YORK, June 17 /PRNewswire/ -- Among US primary care physicians, Novartis earns the highest sales rep relationship scores, followed by Pfizer, Merck, GlaxoSmithKline and Sanofi-Aventis, according to new research from TNS Healthcare. Novartis also takes the top spot in Europe, demonstrating a consistent ability to build strong...

Articles 2008-06-17

Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide® Tablets

PITTSBURGH, June 16 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received tentative approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Irbesartan and Hydrochlorothiazide Tablets, 150 mg/12.5 mg and 300 mg/12.5 mg. ...

Articles 2008-06-16

European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals

Worldwide COGENT-1 Study of CGT-2168 Expands to Europe; Focus on Reducing Gastrointestinal Side Effects of Antiplatelet Therapy MENLO PARK, Calif., June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3 study of its...

Articles 2008-06-16

Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile

LYON, France and SWIFTWATER, Pa., June 16 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization WHO over 3 years for the establishment of an H5N1 vaccine global stockpile. ...

Articles 2008-06-16

Ambien CR® CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

Ambien CRR 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CRR (zolpidem tartrate extended-release) CIV tablets 12.5 mg provided significant improvement in sleep...

Articles 2008-06-10

Sanofi-Aventis will cut 700-800 salespeople in France

PARIS AFP — French pharmaceutical company Sanofi-Aventis said on Monday it planned to cut about a third of its sales representatives in France, or 700-800 jobs. Management "confirms the existence of overstaffing for sales representatives which is estimated at 700-800 jobs," a spokeswoman told AFP, after a report...

Articles 2008-06-09

New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study

Results Presented at the ADA's Annual Scientific Sessions SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the results of the dose-finding study for its new injectable diabetes compound AVE0010, a GLP-1 agonist, were presented at the American Diabetes Association's ADA 68th Annual Scientific Sessions meeting...

Articles 2008-06-07

BestSweet, Largest Manufacturer of Cough Drops in the United-States, Selects XFP-eBR From Elan Software

XFP Electronic Batch Record Software Will Secure and Accelerate BestSweet's Release Process for Finished Goods PRINCETON, New Jersey, June 4 /PRNewswire/ -- Elan Software Systems, a leading provider of Manufacturing Execution System MES software solutions, with a customer portfolio that includes companies such as Baxter, Takeda, sanofi...

Articles 2008-06-04

Obesity market set for huge growth

THE MARKET FOR obesity treatments will grow five-fold by 2016, according to research firm Decision Resources. The category, worth an estimated $478 million in 2006, will grow to $2.7 billion by 2016 in the US, UK, France, Germany, Italy, Spain and Japan, the firm projected. Growth will be most...

Articles 2008-06-01

Pre-launch promotion crucial to brand strategy

GETTING your brand noticed early in its lifespan is crucial to pharma product position strategy said, Corinne Le Goff, VP, marketing, at Sanofi-Aventis. "The most money we can make at the beginning, the better," Le Goff said at the Center for Business Intelligence's 3rd Annual Pharmaceutical Market Research Summit...

Articles 2008-06-01

Zacks Analyst Interview Highlights: Pfizer, Bristol Myers Squibb, Sanofi-Aventis and Merck

CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Jason Napodano, who discusses Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), Sanofi-Aventis (NYSE: SNY) and Merck (NYSE: MRK). Get the most recent insight from Zacks Equity Research with the free Profit from the...

Articles 2008-05-28